APO Research
Talk to an analyst

APO RESEARCH · REPORT

Orphan Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Orphan Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025192 pages

Choose your research edition.

Industry ResearchOrphan Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Orphan Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Orphan Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Orphan Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Orphan Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Orphan Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Orphan Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Orphan Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Orphan Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Orphan Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Orphan Drugs include AstraZeneca, AbbVie, Amgen, Bristol-Myers Squibb, Biogen, Vertex Pharmaceuticals, Pfizer, Eli Lilly and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Orphan Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Orphan Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Orphan Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Orphan Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Orphan Drugs Segment by Company

AstraZeneca

AbbVie

Amgen

Bristol-Myers Squibb

Biogen

Vertex Pharmaceuticals

Pfizer

Eli Lilly

Roche

Novartis

Johnson & Johnson

Sanofi

Takeda

Orphan Drugs Segment by Type

Metabolic Disorders

Pulmonary

Endocrinology

Neurology

Cardio-vascular

Hematology

Oncology

Others

Orphan Drugs Segment by Application

Adult

Teenager

Baby and Child

Other

Orphan Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Orphan Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Orphan Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Orphan Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Orphan Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Orphan Drugs industry.

Chapter 3: Detailed analysis of Orphan Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Orphan Drugsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Orphan Drugs Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Metabolic Disorders Table 3. Key Players of Pulmonary Table 4. Key Players of Endocrinology Table 3. Key Players of Neurology Table 4. Key Players of Cardio-vascular Table 5. Key Players of Hematology Table 6. Key Players of Oncology Table 7. Key Players of Others Table 8. Global Orphan Drugs Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 9. Key Players of Adult Table 10. Key Players of Teenager Table 11. Key Players of Baby and Child Table 12. Key Players of Other Table 13. Global Orphan Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Orphan Drugs Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Orphan Drugs Market Share by Region (2021-2026) Table 16. Global Orphan Drugs Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Orphan Drugs Market Share by Region (2027-2032) Table 18. Orphan Drugs Industry Trends Table 19. Orphan Drugs Industry Drivers Table 20. Orphan Drugs Industry Opportunities and Challenges Table 21. Orphan Drugs Industry Restraints Table 22. Global Orphan Drugs Revenue by Company (US$ Million) & (2021-2026) Table 23. Global Orphan Drugs Revenue Market Share by Company (2021-2026) Table 24. Global Orphan Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 25. Global Orphan Drugs Key Company Head Office and Area Served Table 26. Global Orphan Drugs Company, Product Type & Application Table 27. Global Orphan Drugs Company Establishment Date Table 28. Global Company Market Concentration Ratio (CR5 and HHI) Table 29. Global Orphan Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 30. Global Orphan Drugs Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Orphan Drugs Market Size by Type (2021-2026) & (US$ Million) Table 32. Global Orphan Drugs Market Size by Type (2027-2032) & (US$ Million) Table 33. Global Orphan Drugs Revenue Market Share by Type (2021-2026) Table 34. Global Orphan Drugs Revenue Market Share by Type (2027-2032) Table 35. Global Orphan Drugs Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Orphan Drugs Market Size by Application (2021-2026) & (US$ Million) Table 37. Global Orphan Drugs Market Size by Application (2027-2032) & (US$ Million) Table 38. Global Orphan Drugs Revenue Market Share by Application (2021-2026) Table 39. Global Orphan Drugs Revenue Market Share by Application (2027-2032) Table 40. AstraZeneca Company Information Table 41. AstraZeneca Business Overview Table 42. AstraZeneca Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. AstraZeneca Orphan Drugs Product Portfolio Table 44. AstraZeneca Recent Development Table 45. AbbVie Company Information Table 46. AbbVie Business Overview Table 47. AbbVie Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. AbbVie Orphan Drugs Product Portfolio Table 49. AbbVie Recent Development Table 50. Amgen Company Information Table 51. Amgen Business Overview Table 52. Amgen Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Amgen Orphan Drugs Product Portfolio Table 54. Amgen Recent Development Table 55. Bristol-Myers Squibb Company Information Table 56. Bristol-Myers Squibb Business Overview Table 57. Bristol-Myers Squibb Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Bristol-Myers Squibb Orphan Drugs Product Portfolio Table 59. Bristol-Myers Squibb Recent Development Table 60. Biogen Company Information Table 61. Biogen Business Overview Table 62. Biogen Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Biogen Orphan Drugs Product Portfolio Table 64. Biogen Recent Development Table 65. Vertex Pharmaceuticals Company Information Table 66. Vertex Pharmaceuticals Business Overview Table 67. Vertex Pharmaceuticals Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Vertex Pharmaceuticals Orphan Drugs Product Portfolio Table 69. Vertex Pharmaceuticals Recent Development Table 70. Pfizer Company Information Table 71. Pfizer Business Overview Table 72. Pfizer Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Pfizer Orphan Drugs Product Portfolio Table 74. Pfizer Recent Development Table 75. Eli Lilly Company Information Table 76. Eli Lilly Business Overview Table 77. Eli Lilly Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Eli Lilly Orphan Drugs Product Portfolio Table 79. Eli Lilly Recent Development Table 80. Roche Company Information Table 81. Roche Business Overview Table 82. Roche Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Roche Orphan Drugs Product Portfolio Table 84. Roche Recent Development Table 85. Novartis Company Information Table 86. Novartis Business Overview Table 87. Novartis Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Novartis Orphan Drugs Product Portfolio Table 89. Novartis Recent Development Table 90. Johnson & Johnson Company Information Table 91. Johnson & Johnson Business Overview Table 92. Johnson & Johnson Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 93. Johnson & Johnson Orphan Drugs Product Portfolio Table 94. Johnson & Johnson Recent Development Table 95. Sanofi Company Information Table 96. Sanofi Business Overview Table 97. Sanofi Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 98. Sanofi Orphan Drugs Product Portfolio Table 99. Sanofi Recent Development Table 100. Takeda Company Information Table 101. Takeda Business Overview Table 102. Takeda Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 103. Takeda Orphan Drugs Product Portfolio Table 104. Takeda Recent Development Table 105. North America Orphan Drugs Market Size by Type (2021-2026) & (US$ Million) Table 106. North America Orphan Drugs Market Size by Type (2027-2032) & (US$ Million) Table 107. North America Orphan Drugs Market Size by Application (2021-2026) & (US$ Million) Table 108. North America Orphan Drugs Market Size by Application (2027-2032) & (US$ Million) Table 109. North America Orphan Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. North America Orphan Drugs Market Size by Country (2021-2026) Table 111. North America Orphan Drugs Market Size by Country (2027-2032) Table 112. Europe Orphan Drugs Market Size by Type (2021-2026) & (US$ Million) Table 113. Europe Orphan Drugs Market Size by Type (2027-2032) & (US$ Million) Table 114. Europe Orphan Drugs Market Size by Application (2021-2026) & (US$ Million) Table 115. Europe Orphan Drugs Market Size by Application (2027-2032) & (US$ Million) Table 116. Europe Orphan Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. Europe Orphan Drugs Market Size by Country (2021-2026) Table 118. Europe Orphan Drugs Market Size by Country (2027-2032) Table 119. China Orphan Drugs Market Size by Type (2021-2026) & (US$ Million) Table 120. China Orphan Drugs Market Size by Type (2027-2032) & (US$ Million) Table 121. China Orphan Drugs Market Size by Application (2021-2026) & (US$ Million) Table 122. China Orphan Drugs Market Size by Application (2027-2032) & (US$ Million) Table 123. Asia Orphan Drugs Market Size by Type (2021-2026) & (US$ Million) Table 124. Asia Orphan Drugs Market Size by Type (2027-2032) & (US$ Million) Table 125. Asia Orphan Drugs Market Size by Application (2021-2026) & (US$ Million) Table 126. Asia Orphan Drugs Market Size by Application (2027-2032) & (US$ Million) Table 127. Asia Orphan Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Asia Orphan Drugs Market Size by Country (2021-2026) Table 129. Asia Orphan Drugs Market Size by Country (2027-2032) Table 130. South America, Middle East & Africa Orphan Drugs Market Size by Type (2021-2026) & (US$ Million) Table 131. South America, Middle East & Africa Orphan Drugs Market Size by Type (2027-2032) & (US$ Million) Table 132. South America, Middle East & Africa Orphan Drugs Market Size by Application (2021-2026) & (US$ Million) Table 133. South America, Middle East & Africa Orphan Drugs Market Size by Application (2027-2032) & (US$ Million) Table 134. South America, Middle East & Africa Orphan Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. South America, Middle East & Africa Orphan Drugs Market Size by Country (2021-2026) Table 136. South America, Middle East & Africa Orphan Drugs Market Size by Country (2027-2032) Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Orphan Drugs Product Image Figure 2. Global Orphan Drugs Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Orphan Drugs Market Share by Type: 2025 VS 2032 Figure 4. Metabolic Disorders Image Figure 5. Pulmonary Image Figure 6. Endocrinology Image Figure 7. Neurology Image Figure 8. Cardio-vascular Image Figure 9. Hematology Image Figure 10. Oncology Image Figure 11. Others Image Figure 12. Global Orphan Drugs Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Orphan Drugs Market Share by Application: 2025 VS 2032 Figure 14. Adult Image Figure 15. Teenager Image Figure 16. Baby and Child Image Figure 17. Other Image Figure 18. Global Orphan Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 20. Global Orphan Drugs Market Share by Region: 2025 VS 2032 Figure 21. Years Considered Figure 22. Global Orphan Drugs Market Share by Players in 2025 Figure 23. Global Top 5 and 10 Orphan Drugs Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Global Orphan Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Orphan Drugs Revenue Market Share by Type (2021-2032) Figure 27. Global Orphan Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Orphan Drugs Revenue Market Share by Application (2021-2032) Figure 29. North America Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 30. North America Orphan Drugs Market Share by Type (2021-2032) Figure 31. North America Orphan Drugs Market Share by Application (2021-2032) Figure 32. North America Orphan Drugs Market Share by Country (2021-2032) Figure 33. United States Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 34. Canada Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 35. Mexico Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 36. Europe Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 37. Europe Orphan Drugs Market Share by Type (2021-2032) Figure 38. Europe Orphan Drugs Market Share by Application (2021-2032) Figure 39. Europe Orphan Drugs Market Share by Country (2021-2032) Figure 40. Germany Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 41. France Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 42. U.K. Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 43. Italy Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 44. Russia Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 45. Nordic Countries Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 46. China Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 47. China Orphan Drugs Market Share by Type (2021-2032) Figure 48. China Orphan Drugs Market Share by Application (2021-2032) Figure 49. Asia Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 50. Asia Orphan Drugs Market Share by Type (2021-2032) Figure 51. Asia Orphan Drugs Market Share by Application (2021-2032) Figure 52. Asia Orphan Drugs Market Share by Country (2021-2032) Figure 53. Japan Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 54. South Korea Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 55. Taiwan Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 56. Southeast Asia Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 57. India Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 58. Australia Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 59. South America, Middle East & Africa Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 60. South America, Middle East & Africa Orphan Drugs Market Share by Type (2021-2032) Figure 61. South America, Middle East & Africa Orphan Drugs Market Share by Application (2021-2032) Figure 62. South America, Middle East & Africa Orphan Drugs Market Share by Country (2021-2032) Figure 63. Brazil Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 64. South Africa Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 65. Saudi Arabia Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 66. Turkey Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 67. Argentina Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 68. UAE Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 69. Egypt Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 70. Chile Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Metabolic Disorders
  • Pulmonary
  • Endocrinology
  • Neurology
  • Cardio-vascular
  • Hematology
  • Oncology
  • Others
Applications
  • Adult
  • Teenager
  • Baby and Child
  • Other
Companies covered
  • AstraZeneca
  • AbbVie
  • Amgen
  • Bristol-Myers Squibb
  • Biogen
  • Vertex Pharmaceuticals
  • Pfizer
  • Eli Lilly
  • Roche
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Orphan Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Metabolic Disorders
  5. 1.2.3 Pulmonary
  6. 1.2.4 Endocrinology
  7. 1.2.5 Neurology
  8. 1.2.6 Cardio-vascular
  9. 1.2.7 Hematology
  10. 1.2.8 Oncology
  11. 1.2.9 Others
  12. 1.3 Market Analysis by Application
  13. 1.3.1 Global Orphan Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  14. 1.3.2 Adult
  15. 1.3.3 Teenager
  16. 1.3.4 Baby and Child
  17. 1.3.5 Other
  18. 1.4 Global Market Growth Prospects
  19. 1.5 Global Orphan Drugs Growth Trends by Region
  20. 1.5.1 Global Orphan Drugs Market Size by Region: 2021 VS 2025 VS 2032
  21. 1.5.2 Orphan Drugs Market Size by Region (2021-2026)
  22. 1.5.3 Orphan Drugs Market Size by Region (2027-2032)
  23. 1.6 Assumptions and Limitations
  24. 1.7 Study Goals and Objectives
  25. 1.8 Years Considered
2 Global Orphan Drugs Market Dynamics
  1. 2.1 Orphan Drugs Industry Trends
  2. 2.2 Orphan Drugs Industry Drivers
  3. 2.3 Orphan Drugs Industry Opportunities and Challenges
  4. 2.4 Orphan Drugs Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Orphan Drugs Revenue by Company (2021-2026)
  2. 3.2 Global Orphan Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Orphan Drugs Key Company Head office and Area Served
  4. 3.4 Global Orphan Drugs Company, Product Type & Application
  5. 3.5 Global Orphan Drugs Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Orphan Drugs Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Orphan Drugs Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Orphan Drugs Tier 1, Tier 2, and Tier 3
4 Orphan Drugs Market by Type
  1. 4.1 Global Orphan Drugs Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Orphan Drugs Market Size by Type (2021-2032)
  3. 4.3 Global Orphan Drugs Market Size Share by Type (2021-2032)
5 Orphan Drugs Market by Application
  1. 5.1 Global Orphan Drugs Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Orphan Drugs Market Size by Application (2021-2032)
  3. 5.3 Global Orphan Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 AstraZeneca
  2. 6.1.1 AstraZeneca Company Information
  3. 6.1.2 AstraZeneca Business Overview
  4. 6.1.3 AstraZeneca Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 AstraZeneca Orphan Drugs Product Portfolio
  6. 6.1.5 AstraZeneca Recent Developments
  7. 6.2 AbbVie
  8. 6.2.1 AbbVie Company Information
  9. 6.2.2 AbbVie Business Overview
  10. 6.2.3 AbbVie Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 AbbVie Orphan Drugs Product Portfolio
  12. 6.2.5 AbbVie Recent Developments
  13. 6.3 Amgen
  14. 6.3.1 Amgen Company Information
  15. 6.3.2 Amgen Business Overview
  16. 6.3.3 Amgen Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Amgen Orphan Drugs Product Portfolio
  18. 6.3.5 Amgen Recent Developments
  19. 6.4 Bristol-Myers Squibb
  20. 6.4.1 Bristol-Myers Squibb Company Information
  21. 6.4.2 Bristol-Myers Squibb Business Overview
  22. 6.4.3 Bristol-Myers Squibb Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Bristol-Myers Squibb Orphan Drugs Product Portfolio
  24. 6.4.5 Bristol-Myers Squibb Recent Developments
  25. 6.5 Biogen
  26. 6.5.1 Biogen Company Information
  27. 6.5.2 Biogen Business Overview
  28. 6.5.3 Biogen Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Biogen Orphan Drugs Product Portfolio
  30. 6.5.5 Biogen Recent Developments
  31. 6.6 Vertex Pharmaceuticals
  32. 6.6.1 Vertex Pharmaceuticals Company Information
  33. 6.6.2 Vertex Pharmaceuticals Business Overview
  34. 6.6.3 Vertex Pharmaceuticals Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Vertex Pharmaceuticals Orphan Drugs Product Portfolio
  36. 6.6.5 Vertex Pharmaceuticals Recent Developments
  37. 6.7 Pfizer
  38. 6.7.1 Pfizer Company Information
  39. 6.7.2 Pfizer Business Overview
  40. 6.7.3 Pfizer Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Pfizer Orphan Drugs Product Portfolio
  42. 6.7.5 Pfizer Recent Developments
  43. 6.8 Eli Lilly
  44. 6.8.1 Eli Lilly Company Information
  45. 6.8.2 Eli Lilly Business Overview
  46. 6.8.3 Eli Lilly Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Eli Lilly Orphan Drugs Product Portfolio
  48. 6.8.5 Eli Lilly Recent Developments
  49. 6.9 Roche
  50. 6.9.1 Roche Company Information
  51. 6.9.2 Roche Business Overview
  52. 6.9.3 Roche Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Roche Orphan Drugs Product Portfolio
  54. 6.9.5 Roche Recent Developments
  55. 6.10 Novartis
  56. 6.10.1 Novartis Company Information
  57. 6.10.2 Novartis Business Overview
  58. 6.10.3 Novartis Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Novartis Orphan Drugs Product Portfolio
  60. 6.10.5 Novartis Recent Developments
  61. 6.11 Johnson & Johnson
  62. 6.11.1 Johnson & Johnson Company Information
  63. 6.11.2 Johnson & Johnson Business Overview
  64. 6.11.3 Johnson & Johnson Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Johnson & Johnson Orphan Drugs Product Portfolio
  66. 6.11.5 Johnson & Johnson Recent Developments
  67. 6.12 Sanofi
  68. 6.12.1 Sanofi Company Information
  69. 6.12.2 Sanofi Business Overview
  70. 6.12.3 Sanofi Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Sanofi Orphan Drugs Product Portfolio
  72. 6.12.5 Sanofi Recent Developments
  73. 6.13 Takeda
  74. 6.13.1 Takeda Company Information
  75. 6.13.2 Takeda Business Overview
  76. 6.13.3 Takeda Orphan Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Takeda Orphan Drugs Product Portfolio
  78. 6.13.5 Takeda Recent Developments
7 North America
  1. 7.1 North America Orphan Drugs Market Size (2021-2032)
  2. 7.2 North America Orphan Drugs Market Size by Type
  3. 7.2.1 North America Orphan Drugs Market Size by Type (2021-2026)
  4. 7.2.2 North America Orphan Drugs Market Size by Type (2027-2032)
  5. 7.2.3 North America Orphan Drugs Market Share by Type (2021-2032)
  6. 7.3 North America Orphan Drugs Market Size by Application
  7. 7.3.1 North America Orphan Drugs Market Size by Application (2021-2026)
  8. 7.3.2 North America Orphan Drugs Market Size by Application (2027-2032)
  9. 7.3.3 North America Orphan Drugs Market Share by Application (2021-2032)
  10. 7.4 North America Orphan Drugs Market Size by Country
  11. 7.4.1 North America Orphan Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Orphan Drugs Market Size by Country (2021-2026)
  13. 7.4.3 North America Orphan Drugs Market Size by Country (2027-2032)
  14. 7.4.4 North America Orphan Drugs Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Orphan Drugs Market Size (2021-2032)
  2. 8.2 Europe Orphan Drugs Market Size by Type
  3. 8.2.1 Europe Orphan Drugs Market Size by Type (2021-2026)
  4. 8.2.2 Europe Orphan Drugs Market Size by Type (2027-2032)
  5. 8.2.3 Europe Orphan Drugs Market Share by Type (2021-2032)
  6. 8.3 Europe Orphan Drugs Market Size by Application
  7. 8.3.1 Europe Orphan Drugs Market Size by Application (2021-2026)
  8. 8.3.2 Europe Orphan Drugs Market Size by Application (2027-2032)
  9. 8.3.3 Europe Orphan Drugs Market Share by Application (2021-2032)
  10. 8.4 Europe Orphan Drugs Market Size by Country
  11. 8.4.1 Europe Orphan Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Orphan Drugs Market Size by Country (2021-2026)
  13. 8.4.3 Europe Orphan Drugs Market Size by Country (2027-2032)
  14. 8.4.4 Europe Orphan Drugs Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Orphan Drugs Market Size (2021-2032)
  2. 9.2 China Orphan Drugs Market Size by Type
  3. 9.2.1 China Orphan Drugs Market Size by Type (2021-2026)
  4. 9.2.2 China Orphan Drugs Market Size by Type (2027-2032)
  5. 9.2.3 China Orphan Drugs Market Share by Type (2021-2032)
  6. 9.3 China Orphan Drugs Market Size by Application
  7. 9.3.1 China Orphan Drugs Market Size by Application (2021-2026)
  8. 9.3.2 China Orphan Drugs Market Size by Application (2027-2032)
  9. 9.3.3 China Orphan Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Orphan Drugs Market Size (2021-2032)
  2. 10.2 Asia Orphan Drugs Market Size by Type
  3. 10.2.1 Asia Orphan Drugs Market Size by Type (2021-2026)
  4. 10.2.2 Asia Orphan Drugs Market Size by Type (2027-2032)
  5. 10.2.3 Asia Orphan Drugs Market Share by Type (2021-2032)
  6. 10.3 Asia Orphan Drugs Market Size by Application
  7. 10.3.1 Asia Orphan Drugs Market Size by Application (2021-2026)
  8. 10.3.2 Asia Orphan Drugs Market Size by Application (2027-2032)
  9. 10.3.3 Asia Orphan Drugs Market Share by Application (2021-2032)
  10. 10.4 Asia Orphan Drugs Market Size by Country
  11. 10.4.1 Asia Orphan Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Orphan Drugs Market Size by Country (2021-2026)
  13. 10.4.3 Asia Orphan Drugs Market Size by Country (2027-2032)
  14. 10.4.4 Asia Orphan Drugs Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Orphan Drugs Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Orphan Drugs Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Orphan Drugs Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Orphan Drugs Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Orphan Drugs Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Orphan Drugs Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Orphan Drugs Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Orphan Drugs Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Orphan Drugs Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Orphan Drugs Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Orphan Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Orphan Drugs Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Orphan Drugs Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Orphan Drugs Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst